HomeAI · summaries
Storia in 5 fonti
Psychedelic Stocks Could Explode Higher
Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
zerohedge.com
Psychedelic Stocks Could Explode Higher
Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...
- ·
statnews.com
Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.
- ·
benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…
- ·
investors.com
Biotech Goes Sky-High After LSD Drug Treats Depression
One analyst called this a "best-case" scenario for the company's experimental depression treatment.
- ·
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.
- ·
What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.
- ·
biopharmadive.com
To Wall Street, psychedelics biotechs are more teammates than rivals
Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic field and “bring it even further into the…